化合物GSK1838705A T3079

Product Introduction
Bioactivity


英文名: GSK1838705A

描述: GSK1838705A 是一种高效的、可逆的IGF-IR (IC50:2.0 nM) 和胰岛素受体 (IC50:1.6 nM)抑制剂，也可抑制ALK (IC50:0.5 nM)。

细胞实验: Cells are seeded in 96-well dishes, incubated overnight at 37 °C, and treated with DMSO or GSK1838705A for 72 hours. For the NIH-3T3/LISN proliferation assays, cells are seeded on collagen-coated 96-well tissue culture plates and allowed to adhere for 24 hours. The medium is replaced with serum-free medium and the cells are treated with GSK1838705A for 2 hour. Cells are incubated for 72 hours after addition of IGF-I (30 ng/mL). Cell proliferation is quantified using the CellTiter-Glo Luminescent Cell Viability Assay. IC50s are determined from cytotoxicity curves using a four-parameter curve fit software package (XLfit4(Only for Reference)

激酶实验: Kinase Assays: Baculovirus-expressed glutathione S-transferase-tagged proteins encoding the intracellular domain of IGF-1R (amino acids 957-1367) and IR (amino acids 979-1382) are used for determinations of IC50s by a homogeneous time-resolved fluorescence assay. A filter binding assay is used for appKi determinations using activated IGF-1R and IR kinases. Expanded kinase-selectivity profiling of GSK1838705A is carried out by screening the compound in the KinaseProfiler panel.

体外活性: 在负荷COLO 205肿瘤的小鼠体内,GSK1838705A（30 mg/kg）可抑制80%的肿瘤生长.此外,在负荷HT29异种移植物或BxPC3异种移植物的小鼠体内,GSK1838705A也具有抗肿瘤作用.在负荷NIH-3T3/LISN肿瘤的小鼠体内,GSK1838705A（60 mg/kg,p.o.）抑制77%肿瘤生长,且体重无明显损失.在小鼠体内,通过抑制IR信号,GSK1838705A（60 mg/kg）可使血糖水平短暂增加2倍.GSK1838705A（60 mg/kg）抑制已建立的Karpas-299异种移植物的生长（93%）,但不影响大鼠体重.

体内活性: GSK1838705A可有效抑制细胞中配体诱导的IGF-1R（IC50：85 nM）和IR（IC50：79 nM）磷酸化。GSK1838705A对一系列衍生自固体和血液肿瘤的细胞系,比如L-82/SUP-M2/SK-ES/MCF-7（EC50：24/28/141/203 nM）细胞均有显著抗增殖作用。GSK1838705A可使MCF-7 和NCl-H929细胞在细胞周期的G1 (2N)期积累。GSK1838705A对ALK也有抑制效果（Ki：0.35 nM）,还抑制核仁磷酸蛋白(NPM)-ALK融合细胞的增殖（EC50：24-88 nM）。GSK1838705A对Karpas-299和SR-786细胞中的NPM-ALK磷酸化有显著抑制作用,但对STAT3磷酸化效果一般。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 53.3 mg/mL (100 mM)


关键字: CD246 | Anaplastic lymphoma kinase | inhibit | Cluster of differentiation 246 | Anaplastic lymphoma kinase (ALK) | IGF-1R | GSK1838705A | ALK tyrosine kinase receptor | GSK-1838705A | Inhibitor | Insulin Receptor

相关产品: I-OMe-Tyrphostin AG 538 | Veligrotug | GIP (3-42), human | NBI-31772 | GIP (1-30) amide, porcine acetate | GIP (3-42), human acetate | XL228 | WAY-270250 | Kaempferitrin | NVP-TAE 226

相关库: Anti-Neurodegenerative Disease Compound Library | PI3K-AKT-mTOR Compound Library | Membrane Protein-targeted Compound Library | Cancer Cell Differentiation Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Diabetic Compound Library | Anti-Obesity Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Active Compound Library

化合物GSK1838705A T3079信息由TargetMol中国为您提供，如您想了解更多关于化合物GSK1838705A T3079报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途